NUVA - NuVasive, Inc.
Pre-Market:
Chart Events
Momentum
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 39.65 |
| Open | 39.60 |
| Bid | 36.21 x 800 |
| Ask | 41.83 x 900 |
| Day's Range | 39.36 - 39.68 |
| 52 Week Range | 35.17 - 54.62 |
| Volume | |
| Avg. Volume | 918,984 |
| Market Cap | 2.079B |
| Beta (5Y Monthly) | 1.07 |
| PE Ratio (TTM) | 101.62 |
| EPS (TTM) | 0.39 |
| Earnings Date | Aug 01, 2023 - Aug 07, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 48.73 |
Fair Value
Related Research
ZacksHere's Why You Should Retain Globus Medical (GMED) Stock Now
Investors continue to be optimistic about Globus Medical (GMED) based on the strong performances across geographies and the pending NuVasive acquisition.
ZacksNuVasive (NUVA) Q1 Earnings Beat Estimates, Margins Fall
NuVasive's (NUVA) strong sales across the U.S. Spinal Hardware and U.S. Surgical Support businesses instill optimism.
ZacksNuVasive (NUVA) Tops Q1 Earnings and Revenue Estimates
NuVasive (NUVA) delivered earnings and revenue surprises of 14.63% and 3.11%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
PR NewswireNuVasive Announces First Quarter 2023 Financial Results
NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced financial results for the quarter ended March 31, 2023.
- Thomson Reuters StreetEvents
Q1 2023 Globus Medical Inc Earnings Call
Q1 2023 Globus Medical Inc Earnings Call
Motley FoolGlobus Medical (GMED) Q1 2023 Earnings Call Transcript
Joining today's call from Globus Medical will be Dan Scavilla, president and chief executive officer; and Keith Pfeil, chief financial officer. This review is being made available via webcast, accessible through the Investor Relations section of the Globus Medical website at www.globusmedical.com.
- PR Newswire
NuVasive Announces Conference Call and Webcast of First Quarter 2023 Results
NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, announced today the Company will release its first quarter 2023 results on Wednesday, May 10, 2023, after the close of the market.
Simply Wall St.Is NuVasive, Inc.'s (NASDAQ:NUVA) ROE Of 4.7% Concerning?
Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is...
ZacksIs NuVasive (NUVA) a Great Value Stock Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
GlobeNewswireGlobus Medical Shareholders Approve Share Issuance for Merger with NuVasive
AUDUBON, Pa., April 27, 2023 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, today announced that at the special meeting of shareholders held earlier today its shareholders voted to approve the issuance of shares of Globus Medical Class A common stock in connection with the proposed merger with NuVasive (NASDAQ: NUVA). As previously announced, under the terms of the merger agreement, Globus Medical will issue 0.75 of a share of Globus Medical Cl
- PR Newswire
NuVasive Shareholders Approve Merger Agreement with Globus Medical
NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced that at the special meeting of shareholders held earlier today, its shareholders voted to approve the adoption of the Company's merger agreement with Globus Medical (NYSE: GMED). As previously announced, under the terms of the merger agreement, NuVasive shareholders will receive 0.75 of a share of Globus Medi
ZacksNUVA vs. ABT: Which Stock Is the Better Value Option?
NUVA vs. ABT: Which Stock Is the Better Value Option?
ZacksAre Investors Undervaluing Baxter International (BAX) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
ZacksWhy This 1 Value Stock Could Be a Great Addition to Your Portfolio
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
- PR Newswire
Leading Independent Proxy Advisory Firm Glass Lewis Joins ISS in Recommending NuVasive Shareholders Vote "FOR" the Proposed Merger with Globus Medical
NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced that proxy advisory firm, Glass Lewis & Co., LLC ("Glass Lewis"), recommends that NuVasive shareholders vote "FOR" the shareholder proposal to adopt the merger agreement with Globus Medical (NYSE: GMED) at NuVasive's upcoming special meeting of shareholders ("the special meeting") scheduled for April 27, 2023
- PR Newswire
Leading Independent Proxy Advisory Firm ISS Recommends NuVasive Shareholders Vote "FOR" the Proposed Merger with Globus Medical
NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced that leading independent proxy advisory firm Institutional Shareholder Services ("ISS") recommends that NuVasive shareholders vote "FOR" the shareholder proposal to adopt the merger agreement with Globus Medical (NYSE: GMED) at NuVasive's upcoming special meeting of shareholders ("the special meeting") schedu
- PR Newswire
NuVasive to Participate in Upcoming Global Spine Conferences
NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced its continued participation at various global conferences throughout April and May.
Insider MonkeyHere’s What Happened to NuVasive (NUVA) After Takeover Deal
Investment management company Cove Street Capital recently released its “Small Cap Value Fund” first quarter 2023 investor letter. A copy of the same can be downloaded here. In the first quarter, the fund returned 2.83% compared to 2.74% for the Russell 2000 Index and -0.66% for the Russell 2000 Value Index. In addition, you can check the top […]
- Simply Wall St.
Is There An Opportunity With NuVasive, Inc.'s (NASDAQ:NUVA) 39% Undervaluation?
Key Insights Using the 2 Stage Free Cash Flow to Equity, NuVasive fair value estimate is US$62.57 Current share price...
ZacksWhy Is NuVasive (NUVA) Down 15.9% Since Last Earnings Report?
NuVasive (NUVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
ZacksGlobus Medical (GMED) to Gain From NUVA Deal Amid Rising Costs
The NuVasive acquisition aims to outpace market growth by combining Globus Medical's (GMED) engineering and NuVasive's relations, education and training.
ZacksNuVasive's (NUVA) Precice System Cleared for Pediatric Patients
NuVasive (NUVA) receives FDA 510(k) clearance for using the Precice limb lengthening system for treating pediatric patients.
- PR Newswire
NuVasive Specialized Orthopedics Expands Indications of Precice Limb Lengthening System to Treat Pediatric Patients
NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced that it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the use of its Precice all-internal limb lengthening solution to include pediatric patients*. The expanded clearance extends the clinical benefits of Precice to a wider range of patients.
- Zacks
NuVasive (NUVA), GMED Merger Aids, Macro Woes Mar Growth
According to NuVasive (NUVA), the combined company is set to have an advanced commercial scale and portfolio of clinically proven solutions.
- PR Newswire
NuVasive to Participate in Upcoming Spine Society Annual Conferences
NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced its continued participation at the 2023 Spine Summit held March 16-19 in Miami and the International Meeting on Advanced Spine Techniques (IMAST) held March 22-25 in Dublin.